Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 20;13(2):293.
doi: 10.3390/nu13020293.

A Vicious Cycle of Osteosarcopeniain Inflammatory Bowel Diseases-Aetiology, Clinical Implications and Therapeutic Perspectives

Dorota Skrzypczak  1 , Alicja Ewa Ratajczak  1 , Aleksandra Szymczak-Tomczak  1 , Agnieszka Dobrowolska  1 , Piotr Eder  1 , Iwona Krela-Kaźmierczak  1
Affiliations
Review

A Vicious Cycle of Osteosarcopeniain Inflammatory Bowel Diseases-Aetiology, Clinical Implications and Therapeutic Perspectives

Dorota Skrzypczak et al. Nutrients. .

Abstract

Sarcopenia is a disorder characterized by a loss of muscle mass which leads to the reduction of muscle strength and a decrease in the quality and quantity of muscle. It was previously thought that sarcopenia was specific to ageing. However, sarcopenia may affect patients suffering from chronic diseases throughout their entire lives. A decreased mass of muscle and bone is common among patients with inflammatory bowel disease (IBD). Since sarcopenia and osteoporosis are closely linked, they should be diagnosed as mutual consequences of IBD. Additionally, multidirectional treatment of sarcopenia and osteoporosis including nutrition, physical activity, and pharmacotherapy should include both disorders, referred to as osteosarcopenia.

Keywords: Crohn’s disease; IBD; low muscle mass; low muscle strength; malnutrition; nutritional therapy; sarcopenia; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Shaw S.C., Dennison E.M., Cooper C. Epidemiology of Sarcopenia: Determinants throughout the Lifecourse. Calcif. Tissue Int. 2017;101:229–247. doi: 10.1007/s00223-017-0277-0. - DOI - PMC - PubMed
    1. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169. - DOI - PMC - PubMed
    1. Ooi P.H., Thompson-Hodgetts S., Pritchard-Wiart L., Gilmour S.M., Mager D. Pediatric Sarcopenia: A Paradigm in the Overall Definition of Malnutrition in Children? J. Parenter. Enter. Nutr. 2020;44:407–418. doi: 10.1002/jpen.1681. - DOI - PubMed
    1. Altowati M.M., Shepherd S., McMillan M., McGrogan P., Russell R., Ahmed S.F., Wong S.C. Persistence of Muscle-bone Deficits Following Anti-tumour Necrosis Factor Therapy in Adolescents With Crohn Disease. J. Pediatr. Gastroenterol. Nutr. 2018;67:738–744. doi: 10.1097/MPG.0000000000002099. - DOI - PubMed
    1. Bowser M., Herberg S., Arounleut P., Shi X., Fulzele S., Hill W.D., Isales C.M., Hamrick M.W. Effects of the activin A–myostatin–follistatin system on aging bone and muscle progenitor cells. Exp. Gerontol. 2013;48:290–297. doi: 10.1016/j.exger.2012.11.004. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources